Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study

Baltas, Ioannis; Gilchrist, Mark; Koutoumanou, Eirini; Gibani, Malick M; Meiring, James E; Otu, Akaninyene; Hettle, David; Thompson, Ameeka; Price, James R; Crepet, Anna; Atomode, Abolaji; Crocker-Buque, Timothy; Spinos, Dimitrios; Guyver, Hudson; Tausan, Matija; Somasunderam, Donald; Thoburn, Maxwell; Chan, Cathleen; Umpleby, Helen; Sharp, Bethany; Chivers, Callum; Vaghela, Devan Suresh; Shah, Ronak J; Foster, Jonathan; Hume, Amy; Smith, Christopher; Asif, Ammara; Mermerelis, Dimitrios; Reza, Mohammad Abbas; Haigh, Dominic A; Lamb, Thomas; Karatzia, Loucia; Bramley, Alexandra; Kadam, Nikhil; Kavallieros, Konstantinos; Garcia-Arias, Veronica; Democratis, Jane; Waddington, Claire S; Moore, Luke S P; Aiken, Alexander M

Abstract

Objectives: A novel 'subscription-type' funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked antimicrobial funding model. Methods: An online survey was sent to all infection consultants in NHS acute hospitals in England. Results: The response rate was 31.2% (235/753). Most consultants agreed the model is a welcome development (69.8%, 164/235), will improve treatment of drug-resistant infections (68.5%, 161/235) and will stimulate research and development of new antimicrobials (57.9%, 136/235). Consultants disagreed that the model would lead to reduced carbapenem use and reported increased use of cefiderocol post-implementation. The presence of an antimicrobial pharmacy team, requirement for preauthorization by infection specialists, antimicrobial stewardship ward rounds and education of infection specialists were considered the most effective antimicrobial stewardship interventions. Under the new model, 42.1% (99/235) of consultants would use these antimicrobials empirically, if risk factors for antimicrobial resistance were present (previous infection, colonization, treatment failure with carbapenems, ward outbreak, recent admission to a high-prevalence setting).Significantly higher insurance and diversity values were given to model antimicrobials compared with established treatments for carbapenem-resistant infections, while meropenem recorded the highest enablement value. Use of both 'subscription-type' model drugs for a wide range of infection sites was reported. Respondents prioritized ceftazidime/avibactam for infections by bacteria producing OXA-48 and KPC and cefiderocol for those producing MBLs and infections with Stenotrophomonas maltophilia, Acinetobacter spp. and Burkholderia cepacia. Conclusions: The 'subscription-type' model was viewed favourably by infection consultants in England.

Citation

Baltas I, Gilchrist M, Koutoumanou E, Gibani MM, Meiring JE, Otu A, Hettle D, Thompson A, Price JR, Crepet A, Atomode A, Crocker-Buque T, Spinos D, Guyver H, Tausan M, Somasunderam D, Thoburn M, Chan C, Umpleby H, Sharp B, Chivers C, Vaghela DS, Shah RJ, Foster J, Hume A, Smith C, Asif A, Mermerelis D, Reza MA, Haigh DA, Lamb T, Karatzia L, Bramley A, Kadam N, Kavallieros K, Garcia-Arias V, Democratis J, Waddington CS, Moore LSP, Aiken AM. Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study. JAC Antimicrob Resist. 2023 Aug 1;5(4):dlad091. doi: 10.1093/jacamr/dlad091. PMID: 37533762; PMCID: PMC10391702.

Type

Article